P&G Divests Clearasil, Boots Healthcare Gains Access To U.S. Market
This article was originally published in The Tan Sheet
Executive Summary
Boots Healthcare International's acquisition of the Clearasil acne prevention and treatment brand could be a springboard for creating an OTC marketing presence in the U.S.
You may also be interested in...
Clearasil Anti-Acne Line To Expand With Body Wash, Wipes
Boots Healthcare will add three new products to its core Clearasil line in April, including the brand's first body wash for acne, according to the firm
Clearasil Steps Into Daily Skin Care Shoes Under Boots Ownership
Boots Healthcare is attempting to transform Clearasil from an acne treatment brand to a daily facial skin care line, the UK manufacturer/retailer said
Boots in the U.S.
Firm will devote an additional $171 mil. (€1=$1.42) to support its three "core" brands - Clearasil, Stepsils medicated lozenges and Nuraphen analgesics - over the next four years. Increased support is part of Boots' effort to boost profit from the $84.9 mil. earned in 2001 to $142.5 mil. by 2005; the additional monies will be split between marketing and new product development, company says. New ads for Clearasil, designed by Grey Global Group, will debut in the U.S. in May and feature a "contemporary" perspective on acne. Four new Clearasil products also are slated to debut stateside later this year, firm notes. Boots acquired Clearasil from P&G in 2000 (1"The Tan Sheet" Oct. 23, 2000, p. 7)...